EICHORCondition: Alopecia Areata · Sponsor: Eli Lilly and Company
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Coastal Clinical Research, Inc | Mobile, Alabama, United States | — |
| Johnson Dermatology | Fort Smith, Arkansas, United States | — |
| California Dermatology & Clinical Research Institute | Encinitas, California, United States | — |
| Alliance Research Centers | Irvine, California, United States | — |
| University of CA, Irvine | Irvine, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| Stanford Health Care | Redwood City, California, United States | — |
| University of California Davis-Dermatology | Sacramento, California, United States | — |
| University Clinical Trials, Inc. | San Diego, California, United States | — |
| Mosaic Dermatology | Santa Monica, California, United States | — |
| Yale University School of Medicine | New Haven, Connecticut, United States | — |
+ 63 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03570749